Relationship Between Human Leucocyte Antigen Class I and Class II and Chronic Idiopathic Urticaria Associated With Aspirin and/or NSAIDs Hypersensitivity

Pacor, Maria Luisa; Di Lorenzo, Gabriele; Mansueto, Pasquale; Martinelli, Nicola; Esposito-Pellitteri, Maria; Pradella, Paola; Uxa, Laura; Di Fede, Gaetana; Rini, GiovamBattista; Corrocher, Roberto

doi:https://doi.org/10.1155/MI/2006/62489

Mediators of Inflammation

On this page

Abstract References Copyright Related Articles

Research Communication | Open Access

Volume 2006 | Article ID 062489 | https://doi.org/10.1155/MI/2006/62489

Relationship Between Human Leucocyte Antigen Class I and Class II and Chronic Idiopathic Urticaria Associated With Aspirin and/or NSAIDs Hypersensitivity

Maria Luisa Pacor,¹Gabriele Di Lorenzo,²Pasquale Mansueto,²Nicola Martinelli,¹Maria Esposito-Pellitteri,²Paola Pradella,³Laura Uxa,³Gaetana Di Fede,⁴GiovamBattista Rini,²and Roberto Corrocher¹

Received03 May 2006

Revised30 Jun 2006

Accepted07 Aug 2006

Published04 Oct 2006

Abstract

Background. HLA genes play a role in the predisposition of several diseases. The aim was to analyze the prevalence of HLA class I phenotypes and HLA-DRB1* genotype in patients with CIU associated with ASA and NSAIDs hypersensitivity (AICU). Methods. 69 patients with AICU, and 200 healthy subjects. Results. Subjects with HLA-B44 and HLA-Cw5 antigens were more represented in patients with AICU than in control group. Subjects with HLA-A11, HLA-B13, HLACw4, and HLA-Cw7 antigen were more represented in control group than in patients with AICU. Multiple logistic regression demonstrated an association of HLA-Cw4 and HLA-Cw7 with a lower risk of AICU, whereas carriers of HLA-B44 phenotype had a higher risk of AICU. No differences were found between patients and controls as regards to HLA-DRB1* genotype. Conclusions. We observed an association between some HLA class-I antigens and AICU. To the best of our knowledge this is the first description of such association.

References

M W Greaves, “Urticaria,” Clinical Allergy and Immunology, vol. 16, pp. 381–400, 2002.
View at: Google Scholar
C E Grattan, “The urticaria spectrum: recognition of clinical patterns can help management,” Clinical and Experimental Dermatology, vol. 29, no. 3, pp. 217–221, 2004.
View at: Publisher Site | Google Scholar
C E Grattan, R A Sabroe, and M W Greaves, “Chronic urticaria,” Journal of the American Academy of Dermatology, vol. 46, no. 5, pp. 645–657, 2002.
View at: Publisher Site | Google Scholar
A P Kaplan, “Chronic urticaria: pathogenesis and treatment,” Journal of Allergy and Clinical Immunology, vol. 114, no. 3, pp. 465–474, 2004.
View at: Publisher Site | Google Scholar
G Di Lorenzo, M L Pacor, P Mansueto et al., “Food-additive-induced urticaria: a survey of 838 patients with recurrent chronic idiopathic urticaria,” International Archives of Allergy and Immunology, vol. 138, no. 3, pp. 235–242, 2005.
View at: Publisher Site | Google Scholar
J G Bodmer, S G Marsh, E D Albert et al., “Nomenclature for factors of the HLA system, 1996,” Human Immunology, vol. 53, no. 1, pp. 98–128, 1997.
View at: Publisher Site | Google Scholar
H G Rammensee, T Friede, and S Stevanovic, “MHC ligands and peptide motifs: first listing,” Immunogenetics, vol. 41, no. 4, pp. 178–228, 1995.
View at: Publisher Site | Google Scholar
R Heard, “HLA and autoimmune disease,” in HLA and Disease, R Lechler, Ed., pp. 123–151, Academic Press, London, UK, 1994.
View at: Google Scholar
G Nuki, “Ankylosing spondylitis, HLA B27, and beyond,” Lancet, vol. 351, no. 9105, pp. 767–769, 1998.
View at: Publisher Site | Google Scholar
G Di Lorenzo, M L Pacor, P Mansueto et al., “Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria,” Journal of Allergy and Clinical Immunology, vol. 114, no. 3, pp. 619–625, 2004.
View at: Publisher Site | Google Scholar
G Di Lorenzo, M L Pacor, A M Vignola et al., “Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria patients,” Allergy, vol. 57, no. 12, pp. 1180–1186, 2002.
View at: Publisher Site | Google Scholar
M L Pacor, G Di Lorenzo, D Biasi, M Barbagallo, and R Corrocher, “Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs,” Clinical and Experimental Allergy, vol. 32, no. 3, pp. 397–400, 2002.
View at: Publisher Site | Google Scholar
M L Pacor, G Di Lorenzo, and R Corrocher, “Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid,” Clinical and Experimental Allergy, vol. 31, no. 10, pp. 1607–1614, 2001.
View at: Publisher Site | Google Scholar
S H Kim, J H Choi, K W Lee et al., “The human leucocyte antigen- ${DRB1}^{*}$ $1302 {-DQB1}^{*}$ $0609 {-DPB1}^{*}$ 0201 haplotype may be a strong genetic marker for aspirin-induced urticaria,” Clinical and Experimental Allergy, vol. 35, no. 3, pp. 339–344, 2005.
View at: Publisher Site | Google Scholar
B F O'Donnell, C M O'Neill, D M Francis et al., “Human leucocyte antigen class II associations in chronic idiopathic urticaria,” British Journal of Dermatology, vol. 140, no. 5, pp. 853–858, 1999.
View at: Publisher Site | Google Scholar
P Oztas, M Onder, S Gonen, M O Oztas, and O Soylemezoglu, “Is there any relationship between human leucocyte antigen class II and chronic urticaria? (chronic urticaria and HLA class II),” Yonsei Medical Journal, vol. 45, no. 3, pp. 392–395, 2004.
View at: Google Scholar
J C Roujeau, T N Huynh, C Bracq, J C Guillaume, J Revuz, and R Touraine, “Genetic susceptibility to toxic epidermal necrolysis,” Archives of Dermatology, vol. 123, no. 9, pp. 1171–1173, 1987.
View at: Publisher Site | Google Scholar
J C Roujeau, C Bracq, N T Huyn, E Chaussalet, C Raffin, and N Duedari, “HLA phenotypes and bullous cutaneous reactions to drugs,” Tissue Antigens, vol. 28, no. 4, pp. 251–254, 1986.
View at: Google Scholar
S-I Hung, W-H Chung, L-B Liou et al., “ ${HLA-B}^{*}$ 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 4134–4139, 2005.
View at: Publisher Site | Google Scholar
C S Falk and D J Schendel, “HLA-C revisited. Ten years of change,” Immunologic Research, vol. 16, no. 2, pp. 203–214, 1997.
View at: Google Scholar

Copyright

Copyright © 2006 Maria Luisa Pacor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

241

Downloads

869

Citations